GenVec gets $9.9 million increase in funding for HIV vaccine

By Jennifer Chiou

New York, Oct. 5 - GenVec, Inc. said it received a $9.9 million increase in funding for its HIV vaccine development work with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

The Vaccine Research Center will use GenVec technologies for vaccine development, including its production cell line, 293-ORF6, and the company's adenovector-based vaccine will be used in upcoming Phase II clinical testing.

GenVec works under a subcontract, issued and managed by SAIC-Frederick, which now totals about $50 million and extends through 2008.

Based in Gaithersburg, Md., GenVec is a biopharmaceutical company focused on developing treatments for cancer and cardiac disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.